New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know

A new pancreatic cancer drug called daraxonrasib cut the risk of death by 60% in a Phase 3 trial. What it is, how it works, side effects and when it could reach patients.

Go to News Site